Exim Bank Report: India's MedTech R&D Spending Needs Urgent Boost

A recent study by the Export-Import Bank of India (Exim Bank) reveals significant challenges in India's medical technology (MedTech) sector. The report emphasizes that low investment in research and development (R&D) is a major barrier to innovation and growth in this crucial industry. As India aims to become a global player in MedTech, it is essential to address these funding gaps urgently. The study indicates that India's MedTech sector is facing stagnation in innovation due to inadequate R&D spending. While the global MedTech market is expected to grow significantly, India's share remains limited. This limitation stems from various factors, including insufficient funding, lack of infrastructure, and poor collaboration among industry stakeholders. Globally, the MedTech market is projected to reach USD 600 billion by 2025, driven by technological advancements and rising healthcare demands. In contrast, India's MedTech market, valued at around USD 11 billion, struggles to keep up. The report warns that without a substantial increase in R&D investments, India risks missing out on lucrative opportunities in this fast-evolving sector. R&D is critical for fostering innovation in MedTech. It leads to the creation of new medical devices, diagnostics, and treatment solutions that enhance patient care. The Exim Bank study highlights that countries with strong R&D frameworks tend to excel in MedTech innovation. Currently, India invests only 0.7% of its GDP in R&D, significantly below the global average. The study suggests that this needs to increase to at least 2% to drive meaningful innovation. The funding gap restricts Indian companies from developing advanced technologies and competing globally. Several challenges contribute to low R&D spending in India's MedTech sector. These include funding limitations, regulatory hurdles that complicate product approvals, and a shortage of skilled professionals in the field. To address these issues, the Exim Bank study recommends increased government support for MedTech R&D, promoting public-private partnerships, and investing in skill development programs. In conclusion, the Exim Bank study underscores that low R&D spending is a critical obstacle to innovation in India's MedTech sector. Overcoming this challenge through enhanced investment and collaboration is vital for the industry's growth. As India aspires to lead in MedTech, prioritizing R&D will be essential to unlocking its full potential. Based on reports from Google News — Banking India.